Benlysta in African Americans: FDA Explains Its Decision
This article was originally published in RPM Report
Executive Summary
FDA faced a tough challenge with Benlysta: how to label a lupus drug that failed to show a benefit in African Americans. Here is how FDA officials explained their decision to take a very hands-off approach.
You may also be interested in...
Benlysta Approved: FDA's Silence is Deafening
FDA’s approval of a new lupus therapy had all the elements of a big story to put the agency in a favorable light. But FDA took a decidedly low key approach to the decision, saying it didn’t want to “overhype” the product. That may be a missed opportunity for FDA’s image with key legislators—but it underscores the sense of ambivalence FDA had towards the product all along.
Benlysta Approved: FDA's Silence is Deafening
FDA’s approval of a new lupus therapy had all the elements of a big story to put the agency in a favorable light. But FDA took a decidedly low key approach to the decision, saying it didn’t want to “overhype” the product. That may be a missed opportunity for FDA’s image with key legislators—but it underscores the sense of ambivalence FDA had towards the product all along.
Open Season at Open Sessions: Benlysta May Presage Resurgence of Public Pressure on FDA Committees
FDA would be wise to prepare for a new round of active, emotive open public sessions after the impact of the public testimony at the Benlysta lupus drug review on November 16. It’s been a long-time since a public session has had such a direct impact on creating a pro-approval atmosphere at a committee meeting.